Skip to main content
Explore URMC

menu

Melanoma: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Research Question:
What are the good and bad effects of the sequence of immunotherapy followed by BRAF inhibitor therapy if and when the disease becomes resistant, to the sequence of BRAF inhibitor therapy followed by immunotherapy if and when the disease becomes resistant?

Basic Study Information

Purpose:
The BRAF inhibitor component will include two drugs dabrafenib and trametinib that each have been approved by the FDA for the treatment of this patient population and have also been approved for use in combination due to superior effects relative to the single agent treatments. In addition, the study will involve the addition of the FDA approved agent nivolumab to the standard FDA approved ipilimumab immunotherapy in the hopes that it might further improve the good effects of the immunotherapy component of the treatment sequence.

Location: University of Rochester Medical Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02224781?term=EA6134&rank=1
Study Reference #: CMEL-15088

Lead Researcher (Principal Investigator)

Lead Researcher: Deepak Sahasrabudhe, MD

Study Contact Information

Study Coordinator: Park Bogan
Phone: (585) 276-4415
Email: Park_Bogan@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Melanoma

Return to Search